Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Olmalinc as a diagnostic and therapeutic target for NAFLD, NASH, metabolic syndrome, and hepatic fibrosis

Olmalinc as a diagnostic and therapeutic target for NAFLD, NASH, metabolic syndrome, and hepatic fibrosis

US Patent 11274303 · Granted Mar 15, 2022

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

PAC1 receptor agonists (MAXCAPs) and uses thereof2024
PAC1 receptor agonists (MAXCAPS) and uses thereof2021
Use of pentagastrin to inhibit gastric acid secretion or as a diuretic2014
Use of pentagastrin to inhibit gastric acid secretion or as a diuretic2010
Use of pentagastrin to inhibit gastric acid secretion or as a diuretic2008